Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. (2nd January 2017)

• Record Type: Journal Article
• Authors: Pitt, Jonathan M.; Vétizou, Marie; Gomperts Boneca, Ivo; Lepage, Patricia; Chamaillard, Mathias; Zitvogel, Laurence
• Is Part Of: Oncoimmunology. Volume 6:Number 1(2017)
• Publication Date: 2017-01-02
• Subjects: Anti-CTLA-4 -- Bacteroides -- cancer -- ipilimumab -- microbiota -- microbiome -- T cell; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1132137
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.